TransCode Therapeutics (RNAZ)

• Market cap: $8.23M
• 1 day: -3.54%
• 5 days: -5.27%
• 1 month: -7.33%
• 3 months: 18.16%
• 6 months: -21.09%
• Year to date: 21.35%
• 1 year: -58.35%
• 5 years: -100%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Employees: 7